Purchase this article with an account.
J. A. Roca, L. Wu, M. Maia, J. F. Arevalo, M. H. Berrocal, F. Rodriguez, R. Costa, J. Cardillo, T. Evans, PACORES; Intravitreal Bevacizumab (Avastin(R)) for the Treatment of Macular Edema Secondary to Branch Retinal Vein Occlusion: Results of the Pan-American Collaborative Retina Study Group (PACORES). Invest. Ophthalmol. Vis. Sci. 2007;48(13):91.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To report the short-term anatomic and visual outcomes after an intravitreal bevacizumab (Avastin) injection in patients with branch retinal vein occlusion (BRVO).
Interventional retrospective multicenter study at 7 centers in 6 countries of 36 eyes of 36 patients with macular edema secondary to BRVO who were treated with at least one intravitreal injection of bevacizumab at a dose of 1.25 mg or 2.5 mg. Patients underwent ETDRS visual acuity (VA) testing, ophthalmoscopic examination, optical coherence tomography (OCT) and fluorescein angiography (FA) at baseline and follow-up visits.
Thirty six eyes with macular edema secondary to BRVO were injected on average 21 months after the diagnosis (range 3 months to 86 months). The average follow-up is of 29.4 weeks (range from 4 to 52 weeks). The baseline logMAR was 1.00 ± 0.53 (range 0.20 to 2.30). At 1 month the average logMAR was 0.68 ± 0.41 (p=0.0001), at 3 months 0.59 ± 0.43 (p<0.0001), at 6 months 0.53 ± 0.38 (p<0.0001) and at the last follow-up was 0.59 ± 0.42 (p<0.0001). The baseline mean central macular thickness measured by OCT decreased from 439 ± 215 µm to 283 ±126 µm at 1 month (p<0.0001), 248 ± 110 µm at 3 months (p<0.0001), 200 ± 144 µm at 6 months (p<0.0001) and 267 Â± 102 Âµm at the last follow-up (p<0.0001). On average, patients received 1.4 injections per eye (range 1 to 4). Five (14%) eyes required a second injection at a mean of 8 weeks (range from 4 to 13 weeks), four (11.1%) eyes required a third and another (2.8%) required a fourth injection. At the last follow-up, 9 eyes (26%) remained within 3 lines of baseline VA, 27 eyes (74%) improved 3 or more lines of ETDRS VA and none lost more than 3 lines of ETDRS VA. No serious ocular or systemic adverse events were observed.
Intravitreal bevacizumab at doses up to 2.5 mg may provide stability or improvement in VA and OCT in BRVO. Although the follow-up in our study is short, the results appear promising.
This PDF is available to Subscribers Only